Business
Press Release Nov 16 2022
Suven Life Sciences Limited has informed the Exchange about press release dated 16-Nov-2022 titled Suven Life Sciences Limited Announces Randomization of First Patient in Phase-3 Global Clinical Trial of Masupirdine (SUVN-502) for the Treatment of Agitation in Patients with Dementia of the Alzheime
About this update from Suven Life Sciences Limited
[{"type":"text","content":" Suven Life Sciences Limited has informed the Exchange about press release dated 16-Nov-2022 titled Suven Life Sciences Limited Announces Randomization of First Patient in Phase-3 Global Clinical Trial of Masupirdine (SUVN-502) for the Treatment of Agitation in Patients with Dementia of the Alzheime View Attachment","length":453,"tagName":"div"}]